Cyclosporine or tacrolimus

Which is the better partner for Myfortic or CellCept?

P. C. Lee, S. S. Chang, S. C. Shieh, Z. C. Wu, W. M. Wang, Jung-Der Wang, Chung-Jye Hung, Yih-Jyh Lin, T. C. Chou, Ren-Hao Chan

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Mycophenolic acid (MPA) pharmacokinetics using the mycophenolate mofetil (CellCept) formulation are known to differ between patients receiving tacrolimus (FK) or cyclosporine (CyA), but only limited data exist concerning concomitant use of FK or CyA with enteric-coated mycophenolate sodium (EC-MPS; Myfortic). This retrospective study compared the drug interactions with the mycophenolic acid blood levels using different immunosuppressants and their relation to graft survival. Patients and methods: We studied MPA levels in posttransplant sera from 298 renal transplant recipients. Results: Patients receiving immunosuppression with CyA + Myfortic showed 94% at 5- and 10-year graft survivals, which were better than CyA + CellCept (75%, 63%). This combination suppressed posttransplant human leukocyte antigen (HLA) antibody development significantly (P =.03) with higher MPA levels. Conclusion: Patients immunosuppressed with CyA + Myfortic showed higher MPA levels and lower posttransplant HLA antibody development as well as the best graft survival. CyA + Myfortic or FK + Cellcept may be better combinations.

Original languageEnglish
Pages (from-to)137-139
Number of pages3
JournalTransplantation Proceedings
Volume44
Issue number1
DOIs
Publication statusPublished - 2012 Jan 1

Fingerprint

Mycophenolic Acid
Tacrolimus
Cyclosporine
Graft Survival
HLA Antigens
Antibodies
Immunosuppressive Agents
Drug Interactions

All Science Journal Classification (ASJC) codes

  • Surgery
  • Transplantation

Cite this

Lee, P. C. ; Chang, S. S. ; Shieh, S. C. ; Wu, Z. C. ; Wang, W. M. ; Wang, Jung-Der ; Hung, Chung-Jye ; Lin, Yih-Jyh ; Chou, T. C. ; Chan, Ren-Hao. / Cyclosporine or tacrolimus : Which is the better partner for Myfortic or CellCept?. In: Transplantation Proceedings. 2012 ; Vol. 44, No. 1. pp. 137-139.
@article{a73cb4579ed5441cadd895a892188a58,
title = "Cyclosporine or tacrolimus: Which is the better partner for Myfortic or CellCept?",
abstract = "Background: Mycophenolic acid (MPA) pharmacokinetics using the mycophenolate mofetil (CellCept) formulation are known to differ between patients receiving tacrolimus (FK) or cyclosporine (CyA), but only limited data exist concerning concomitant use of FK or CyA with enteric-coated mycophenolate sodium (EC-MPS; Myfortic). This retrospective study compared the drug interactions with the mycophenolic acid blood levels using different immunosuppressants and their relation to graft survival. Patients and methods: We studied MPA levels in posttransplant sera from 298 renal transplant recipients. Results: Patients receiving immunosuppression with CyA + Myfortic showed 94{\%} at 5- and 10-year graft survivals, which were better than CyA + CellCept (75{\%}, 63{\%}). This combination suppressed posttransplant human leukocyte antigen (HLA) antibody development significantly (P =.03) with higher MPA levels. Conclusion: Patients immunosuppressed with CyA + Myfortic showed higher MPA levels and lower posttransplant HLA antibody development as well as the best graft survival. CyA + Myfortic or FK + Cellcept may be better combinations.",
author = "Lee, {P. C.} and Chang, {S. S.} and Shieh, {S. C.} and Wu, {Z. C.} and Wang, {W. M.} and Jung-Der Wang and Chung-Jye Hung and Yih-Jyh Lin and Chou, {T. C.} and Ren-Hao Chan",
year = "2012",
month = "1",
day = "1",
doi = "10.1016/j.transproceed.2011.12.023",
language = "English",
volume = "44",
pages = "137--139",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "1",

}

Cyclosporine or tacrolimus : Which is the better partner for Myfortic or CellCept? / Lee, P. C.; Chang, S. S.; Shieh, S. C.; Wu, Z. C.; Wang, W. M.; Wang, Jung-Der; Hung, Chung-Jye; Lin, Yih-Jyh; Chou, T. C.; Chan, Ren-Hao.

In: Transplantation Proceedings, Vol. 44, No. 1, 01.01.2012, p. 137-139.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cyclosporine or tacrolimus

T2 - Which is the better partner for Myfortic or CellCept?

AU - Lee, P. C.

AU - Chang, S. S.

AU - Shieh, S. C.

AU - Wu, Z. C.

AU - Wang, W. M.

AU - Wang, Jung-Der

AU - Hung, Chung-Jye

AU - Lin, Yih-Jyh

AU - Chou, T. C.

AU - Chan, Ren-Hao

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Background: Mycophenolic acid (MPA) pharmacokinetics using the mycophenolate mofetil (CellCept) formulation are known to differ between patients receiving tacrolimus (FK) or cyclosporine (CyA), but only limited data exist concerning concomitant use of FK or CyA with enteric-coated mycophenolate sodium (EC-MPS; Myfortic). This retrospective study compared the drug interactions with the mycophenolic acid blood levels using different immunosuppressants and their relation to graft survival. Patients and methods: We studied MPA levels in posttransplant sera from 298 renal transplant recipients. Results: Patients receiving immunosuppression with CyA + Myfortic showed 94% at 5- and 10-year graft survivals, which were better than CyA + CellCept (75%, 63%). This combination suppressed posttransplant human leukocyte antigen (HLA) antibody development significantly (P =.03) with higher MPA levels. Conclusion: Patients immunosuppressed with CyA + Myfortic showed higher MPA levels and lower posttransplant HLA antibody development as well as the best graft survival. CyA + Myfortic or FK + Cellcept may be better combinations.

AB - Background: Mycophenolic acid (MPA) pharmacokinetics using the mycophenolate mofetil (CellCept) formulation are known to differ between patients receiving tacrolimus (FK) or cyclosporine (CyA), but only limited data exist concerning concomitant use of FK or CyA with enteric-coated mycophenolate sodium (EC-MPS; Myfortic). This retrospective study compared the drug interactions with the mycophenolic acid blood levels using different immunosuppressants and their relation to graft survival. Patients and methods: We studied MPA levels in posttransplant sera from 298 renal transplant recipients. Results: Patients receiving immunosuppression with CyA + Myfortic showed 94% at 5- and 10-year graft survivals, which were better than CyA + CellCept (75%, 63%). This combination suppressed posttransplant human leukocyte antigen (HLA) antibody development significantly (P =.03) with higher MPA levels. Conclusion: Patients immunosuppressed with CyA + Myfortic showed higher MPA levels and lower posttransplant HLA antibody development as well as the best graft survival. CyA + Myfortic or FK + Cellcept may be better combinations.

UR - http://www.scopus.com/inward/record.url?scp=84863345151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863345151&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2011.12.023

DO - 10.1016/j.transproceed.2011.12.023

M3 - Article

VL - 44

SP - 137

EP - 139

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 1

ER -